findmyKOL
Clinical trialNCT07200089RecruitingPhase 1Interventional

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

SponsorWashington University School of MedicineEnrollment52Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Michael Slade, M.D., M.S.C.I

    Washington University School of Medicine

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Washington University School of Medicine

    St Louis, Missouri, United States

    Arun Cumpelik, M.D.Feng Gao, M.D., Ph.D.John F DiPersio, M.D., Ph.D.Michael Slade, M.D., M.S.C.I
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Jun 2026
Primary completion
10 Mar 2028
Completion
31 Dec 2028
Last update posted
10 Jun 2026
Registered enrollment
52
Registry id
NCT07200089

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.